当前位置:首页 - 行情中心 - 山东药玻(600529) - 财务分析 - 利润表

山东药玻

(600529)

  

流通市值:141.68亿  总市值:141.68亿
流通股本:6.64亿   总股本:6.64亿

利润表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、营业总收入2,373,844,830.371,242,455,243.55,125,270,640.683,824,950,899.24
  营业收入2,373,844,830.371,242,455,243.55,125,270,640.683,824,950,899.24
二、营业总成本1,901,614,186.9982,600,179.314,013,019,482.722,966,963,655.72
  营业成本1,622,904,283.33867,166,737.373,499,338,477.092,597,119,472.67
  税金及附加25,032,717.9410,446,215.5154,549,603.340,707,950.22
  销售费用45,138,736.0620,893,173.48129,736,903.0992,248,624.66
  管理费用128,031,063.8241,187,436.65215,768,838.57146,586,178.09
  研发费用95,674,626.7949,680,967.32151,763,172.77115,324,642.87
  财务费用-15,167,241.04-6,774,351.02-38,137,512.1-25,023,212.79
  其中:利息费用11,153.734,942.6225,183.4519,912.84
  其中:利息收入7,888,019.253,526,865.6221,211,803.9318,637,370.01
三、其他经营收益
  加:公允价值变动收益6,447,381.914,105,310.6824,463,237.3119,843,946.28
  加:投资收益7,227,203.393,986,280.2211,633,529.789,219,631.55
  资产处置收益417,482.36109.46329,546.95329,075.59
  资产减值损失(新)-48,839,146.75--61,157,836.83-30,162,527.45
  信用减值损失(新)-4,459,841.93-6,196,742.54-1,283,636.72-4,125,156.64
  其他收益11,068,719.245,089,395.4926,524,819.3520,103,532.17
四、营业利润444,092,441.69266,839,417.51,112,760,817.8873,195,745.02
  加:营业外收入1,103,350.42868,048.553,398,144.752,656,470.78
  减:营业外支出3,648,149.62792,935.385,353,909.363,653,076.07
五、利润总额441,547,642.49266,914,530.671,110,805,053.19872,199,139.73
  减:所得税费用70,406,020.4943,285,095.79167,813,747.78151,767,993.07
六、净利润371,141,622223,629,434.88942,991,305.41720,431,146.66
(一)按经营持续性分类
  持续经营净利润371,141,622223,629,434.88942,991,305.41720,431,146.66
(二)按所有权归属分类
  归属于母公司股东的净利润371,141,622223,629,434.88942,991,305.41720,431,146.66
  扣除非经常损益后的净利润354,997,295.64214,187,271.01903,572,504.05689,013,664.85
七、每股收益
  (一)基本每股收益0.560.341.421.09
  (二)稀释每股收益0.560.341.421.09
九、综合收益总额371,141,622223,629,434.88942,991,305.41720,431,146.66
  归属于母公司股东的综合收益总额371,141,622223,629,434.88942,991,305.41720,431,146.66
公告日期2025-08-262025-04-252025-04-252024-10-29
审计意见(境内)标准无保留意见
TOP↑